Introduction
Testicular cancer is a relatively rare malignancy affecting mostly young men of working age. Still, it is the most common solid tumor in men aged 20 to 34 years. 1, 2 The incidence of testicular cancer in Finland is 5.8 per 100,000 men, which is comparable with that of the United States. 3, 4 The incidence has been on the rise for 40 years and is estimated to further increase in the next decade.
1,2,5
The age-adjusted 5-year relative survival rate of patients with testicular cancer in Finland is 95% because of the high sensitivity to chemotherapy. 4 Although testicular cancer, in general, has an excellent prognosis, the expected 5-year survival of patients with brain metastases (BM) at initial diagnosis is <50%. 6, 7 Because surgical treatment and stereotactic radiotherapy are rarely applicable, the most frequently used therapy for BM remains multimodality treatment with chemotherapy and whole brain radiation therapy (WBRT). WBRT is possibly related to survival benefit, but also leads to cognitive decline and long-term neurotoxicity. 7, 8 The most common deleterious cognitive effects are impaired memory and executive function. 9 Of patients treated with WBRT 50% to 80% show a decline in neurocognitive tests and 12% to 38% have impaired Mini-Mental State Examination scores. 10 Progressive delayed brain toxicity has also been described.
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Herein we report a case of a patient with BM of testicular cancer treated with chemotherapy in conjunction with bloodebrain barrier disruption (BBBD). This promising treatment combines transient disruption of the bloodebrain barrier with hyperosmolar intraarterial mannitol infusion and simultaneous intra-arterial administration of chemotherapy. This is known to drastically increase the intracranial and intratumoral concentrations of chemotherapy agents. 12, 13 Treating BM with BBBD therapy, we were able to avoid the deleterious cognitive effects of WBRT with a complete treatment response.
Clinical Practice Points
Testicular cancer with brain metastases is related to poor prognosis because the penetration of chemotherapeutic agents is decreased by the bloodebrain barrier.
The standard treatment of brain metastases-whole brain radiation therapy combined with chemotherapyis related to a limited increase in survival and considerable deleterious cognitive effects. The bloodebrain barrier can be transiently disrupted using hyperosmolar intra-arterial mannitol injection.
When combined with intra-arterial chemotherapy, therapeutic intratumoral concentrations can be attained.
In experienced centers, bloodebrain barrier disruption therapy is relatively safe with a low incidence of catheter-related complications. Bloodebrain barrier disruption therapy is a promising treatment modality for brain metastases as an alternative to whole brain radiation therapy.
Case
A 25-year-old man was admitted to the emergency department of Oulu University Hospital for a headache, visual field loss, and fever spanning 3 days. A week before the admission the patient was assessed for a supraclavicular mass with a diameter of 4 cm and a fine-needle aspiration was performed. A head magnetic resonance imaging (MRI) scan revealed 10 to 15 contrast-enhancing tumors in the cerebrum and cerebellum in both hemispheres ( Figure 1, 1A-2C) . A computed tomography scan of the chest, abdomen, and pelvis showed several contrast-enhancing nodules in the lungs and lymphadenopathy in the upper abdomen and mediastinum. Ultrasonography located a primary tumor with a diameter of 13 mm and irregular borders in the left testicle. Serum and plasma tumor markers betahuman chorionic gonadotropin (20,000 U/L) and lactate dehydrogenase (LDH) (805 U/L) were elevated indicating an advanced disease. Alpha-fetoprotein was within reference values. A radical orchiectomy from the inguinal incision was performed within 3 days.
The surgical sample showed scar tissue with no viable tumor cells suggesting a regressed tumor. The fine-needle aspiration sample of the supraclavicular mass revealed the final diagnosis of advanced choriocarcinoma and metastases in the brain, lungs, abdomen, and mediastinum.
The patient was treated with 4 cycles of BEP (bleomycin, etoposide, cisplatin) as recommended by European Consensus Conference on Diagnosis and Treatment of Germ Cell Cancer report for patients with poor prognosis according to International Germ Cell Consensus Classification Group. 8, 14 Trends in the tumor marker levels are shown in Figure 2 . After 4 cycles of BEP, fluorodeoxyglucose (FDG) positron emission tomography scan showed accumulation of FDG in lymph nodes on the neck and para-aortic region and in the pulmonary nodules. The nuchal lymph node was surgically resected for histologic study, which revealed a necrotic tumor with no viable tumor cells. However, elevated tumor markers beta-human chorionic gonadotropin and LDH (128 U/L The treatment of choice for multiple BM unresponsive to chemotherapy is WBRT. Considering the patient's young age and long working life expectations the harmful effects of WBRT on cognitive abilities would have been particularly disabling. Because our clinic is one of the few centers in the world administering BBBD chemotherapy, the possibility of this experimental treatment was discussed with the patient. He agreed to 4 cycles of BBBD with a combination of carboplatin, cyclophosphamide, and etoposidedrugs also used in the standard treatment of choriocarcinoma. We have previously described the treatment protocol in detail. 15, 16 Three treatments were administered to each internal carotid artery and 1 treatment to vertebral arteries. Complete treatment response was observed in MRI after the second cycle. MRI before and after BBBD therapy is shown in Figure 1 . A mild hearing loss caused by platinum-based chemotherapy was noticed in audiogram after the second round of BBBD therapy. The subsequent doses of carboplatin were reduced, and the hearing loss did not progress in 9 months of follow-up. As previously planned, after the BBBD therapy, the patient started a high-dose intravenous chemotherapy regimen with carboplatin and etoposide and underwent autologous stem cell transplantation.
Thirty-two months from the last BBBD therapy, the patient remained in complete remission: the tumor markers were low and imaging studies of brain, chest, abdomen, and pelvis showed no detectable active tumor.
Discussion
Despite the excellent prognosis of testicular cancer and high sensitivity to chemotherapy, the 5-year survival in patients who develop BM during first-line treatment is <5%. 17 In 32 months of follow-up, our patient remained in remission. In comparison, the progression-free survival rate of patients with germ cell tumor with BM at initial diagnosis is 30% at 3 years. 7 In the case of BM, the bloodebrain barrier prevents traditional intravenous drug delivery to tumor tissue. Although the development of surgical treatment and stereotactic radiation therapy has given hope for some patients, these modalities cannot be applied for multiple metastases, and WBRT remains the cornerstone of the treatment. The neurotoxicity of WBRT is especially detrimental for developing children and young adults with long working life expectancy. BBBD therapy is a promising treatment for BM with the potential to avoid the adverse cognitive effects of WBRT. In addition to BBBD therapy, the patient received high-dose chemotherapy, which might be related to higher long-term survival rates in testicular cancer with BM. 18, 19 However, we find this option doubtful because the radiological response to BBBD was seen before initiating high-dose chemotherapy. Moreover, the chemotherapeutic agents used during the high-dose therapy (carboplatin and etoposide), are known to have a low penetrance in the central nervous system.
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Thus, we believe the sustained response in the brain and the favorable prognosis seen in our patient is attributable to BBBD therapy. The assessment of the absent cognitive impairment was limited to the patient's subjective evaluation of symptoms and no neuropsychological testing was performed. However, McAllister et al have previously shown in a cohort of patients with primary central nervous system lymphoma that the therapy does not significantly impair cognitive capabilities. 22 Our article describes a successful treatment of chorionic carcinoma and BM with BBBD therapy. To our knowledge, 5 cases of patients with germ cell tumor BM treated with BBBD have been reported previously. Two achieved complete response, 1 partial response, and 1 stable disease evaluated using the MacDonald criteria. 21, 22 Promising results with BBBD have been reported with BM of ovarian carcinoma and adenocarcinomas 23 and several primary central nervous system 16, 24 and astrocytomas. 26 The safety issues with BBBD therapy are similar to any chemotherapy. Most common clinically significant adverse effects are cytopenias and thromboembolic events caused by arterial access. Mortality has been described with only aggressively growing tumors, such as glioblastoma. 24 Further research is needed to assess the efficacy of BBBD therapy in testicular cancer BM. Still, our study illustrates the opportunity to protect cognitive abilities with good tumor response using BBBD in patients with poor prognosis for whom the treatment options are limited.
Conclusion
Treatment of testicular cancer with BM is problematic because the conventional intravenous chemotherapy is rendered ineffective because of the bloodebrain barrier. This case report shows the use of BBBD therapy as an alternative to WBRT. With BBBD therapy, chemotherapy can be effectively delivered to target tumor across the bloodebrain barrier.
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